CN112057427A

CN112057427A - Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof

Info

Publication number: CN112057427A
Application number: CN201910495942.4A
Authority: CN
Inventors: 仇罡; 沈一唯; 范文源; 徐铄; 吕会茹; 卞佳琳; 杜争鸣
Original assignee: Baiji Shenzhou Suzhou Biotechnology Co ltd
Current assignee: Baiji Shenzhou Suzhou Biotechnology Co ltd
Priority date: 2019-06-10
Filing date: 2019-06-10
Publication date: 2020-12-11
Anticipated expiration: 2039-06-10
Also published as: CN112057427B

Abstract

The invention provides an oral solid tablet containing (S) -7- [4- (1-acryloyl piperidine) ] -2- (4-phenoxyphenyl) 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a ] pyrimidine-3-formamide and a preparation method thereof. The oral solid tablet disclosed by the invention has good drug release characteristics, is convenient to take, is quick and efficient to release, has no special requirements on equipment, is simple in preparation process, can ensure the stability of the preparation, is convenient to transport and store, and is suitable for large-scale production.

Description

Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof

The technical field is as follows:

the invention belongs to the field of pharmaceutical preparations, and describes an oral solid tablet containing Bruton' S Tyrosine Kinase (BTK) inhibitor, in particular (S) -7- [4- (1-acryloyl piperidine) ] -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a ] pyrimidine-3-formamide, and a preparation method thereof.

Background art:

international application WO2014173289A discloses a novel Bruton' S Tyrosine Kinase (BTK), more specifically (S) -7- [4- (1-acryloylpiperidine) ] -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a ] pyrimidine-3-carboxamide (generic name zanrubutinib), having the chemical structure:

zanubrutinib belongs to the second generation BTK inhibitors, which irreversibly inactivate the enzyme by covalently binding to tyrosine kinase. It can be used for treating B lymphocyte tumor (including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinemia (WM), Follicular Lymphoma (FL), non-germinal center subtype diffuse large B cell lymphoma (non-GCB DLBCL), etc.) alone or in combination with other drugs.

The raw material drug of Zanbrutinib is slightly hygroscopic. The DSC result shows that the compound has a definite endothermic peak when melting, and the initial temperature and the peak temperature are 139 ℃ and 144 ℃ respectively. The melting point of the bulk drug is 145 ℃ which is 150 ℃ lower than the ideal melting point of tablet development, and the material viscosity is relatively high, which brings great challenges to the tablet development and large-scale industrial production of Zanbrutinib. In addition, the solubility of Zanubrutinib is pH-dependent and belongs to class II (low solubility, high permeability) drugs of the classification system of biopharmaceuticals, and therefore, there is an urgent need to develop a Zanubrutinib tablet in which an active ingredient can be rapidly dissolved out from the formulation, thereby maintaining the rapid release of a drug in the whole intestinal tract to have good bioavailability.

Disclosure of Invention

In order to overcome the defects of Zanbutritinib raw material medicine (API) in the aspect of physicochemical properties, such as large viscosity, poor fluidity, poor solubility and the like, and ensure good dissolution rate of the medicine, the invention provides an oral solid tablet containing a Bruton's tyrosine kinase inhibitor Zanbutritinib and a preparation method thereof. The inventors of the present invention have surprisingly found that a certain amount of colloidal silicon dioxide as a glidant and other excipients contributes significantly to improve the problem of drug sticking and to ensure a good dissolution rate of the drug. The Zanbutritinib oral solid tablet can be rapidly released in a medium containing sodium dodecyl sulfate and having pH of 1.2(HCl), for example, the dissolution rate can reach more than 80% within 30-60 min when some prescription auxiliary materials are mixed; preferably, the Zanbutritinib can be dissolved out to more than 95% within 30 minutes in some prescription auxiliary material ratios. In addition, the Zanbrutinib oral solid tablet has no special requirements on production equipment, and has the advantages of simple preparation process, stable product and low production cost.

In one aspect of the present invention, there is provided an oral solid tablet containing Zanubrutinib, which contains: (1) 20 to 70 percent (mass percent) of Zanbrutinib, preferably 30 to 50 percent (mass percent); (2) one or more pharmaceutically acceptable excipients.

In some embodiments of the present invention, the Zanubrutinib may be in any solid form, such as crystalline form (e.g., form a disclosed in WO 2018033853A), amorphous form, or a mixture of crystalline and amorphous forms. Preferably, the Zanubrutinib is form a, amorphous, or a mixture of form a and amorphous. In some embodiments of the invention, the particle size of the Zanubrutinib is below 40 μm.

In some embodiments, the form a has an X-ray powder diffraction pattern comprising diffraction peaks having angle values independently selected from the group consisting of: about 14.8 ± 0.2 °, 15.6 ± 0.2 °, 16.4 ± 0.2 ° and 21.4 ± 0.2 °. In some embodiments, the form a has an X-ray powder diffraction pattern comprising diffraction peaks having angle values independently selected from the group consisting of: about 12.2 + -0.2 deg., 12.9 + -0.2 deg., 14.8 + -0.2 deg., 15.6 + -0.2 deg., 16.4 + -0.2 deg., and 21.4 + -0.2 deg.. In some embodiments, the form a has an X-ray powder diffraction pattern comprising diffraction peaks having angle values independently selected from the group consisting of: about 12.2 + -0.2 deg., 12.9 + -0.2 deg., 14.8 + -0.2 deg., 15.6 + -0.2 deg., 16.4 + -0.2 deg., 17.7 + -0.2 deg., 18.5 + -0.2 deg., 20.7 + -0.2 deg., and 21.4 + -0.2 deg.. In some embodiments, the form a has an X-ray powder diffraction pattern substantially in accordance with figure 1.

In some embodiments of the invention, the excipient is optionally selected from the group consisting of fillers, binders, disintegrants, wetting agents, glidants, lubricants, and any combination thereof.

In some embodiments of the invention, the filler is selected from the group consisting of starch, sucrose, microcrystalline cellulose, mannitol, lactose, pregelatinized starch, glucose, maltodextrin, cyclodextrin, cellulose, silicified microcrystalline cellulose, and any combination thereof.

In some embodiments of the invention, the filler is lactose, which is present in an amount of about 20% to 70%, preferably about 40% to 60%, all by weight.

In some embodiments of the present invention, the filler is microcrystalline cellulose, microcrystalline cellulose is an internal filler, and the microcrystalline cellulose filler is present in an amount of about 10% to about 50%, preferably about 30% to about 50%, by weight.

In some embodiments of the invention, where the filler is a combination of lactose and microcrystalline cellulose, the amounts of lactose and microcrystalline cellulose are about 0% to about 70% and about 0% to about 50%, preferably about 40% to about 60% and about 4% to about 10%, respectively, by mass.

In some embodiments of the invention, the binder is selected from the group consisting of starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, gelatin, sucrose, and any combination thereof.

In some embodiments of the present invention, the binder is hypromellose, and the content of hypromellose is about 0-10%, preferably about 0-5%, by mass.

In some embodiments of the invention, the binder is croscarmellose sodium, and is present in an amount of about 0% to 10%, preferably about 0% to 5%, all by weight.

In some embodiments of the invention, the disintegrant is selected from the group consisting of sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, croscarmellose, methylcellulose, pregelatinized starch, sodium alginate, and any combination thereof.

In some embodiments of the invention, the disintegrant is croscarmellose sodium, and the croscarmellose sodium content is from about 0.5% to 5%, preferably from about 1% to 3%, all by mass.

In some embodiments of the invention, the wetting agent is Sodium Lauryl Sulfate (SLS) which is present in an amount of about 0% to 5%, preferably 0.5% to 1.0%, all by mass.

In some embodiments of the invention, the glidant is selected from the group consisting of powdered cellulose, magnesium trisilicate, colloidal silicon dioxide, talc, and any combination thereof.

In some embodiments of the invention, the glidant is colloidal silicon dioxide, and the colloidal silicon dioxide is present in an amount of about 0.1 to 20 percent by mass. When the content of colloidal silicon dioxide is less than 0.1% (mass%), colloidal silicon dioxide cannot effectively disperse API, so that rapid disintegration of the tablet and dissolution of API cannot be ensured; and when the content of the colloidal silica is more than 20 mass%, it is disadvantageous for commercial production due to a large volume. More preferably, the colloidal silica is present in an amount of about 4% to 8% by mass.

In some embodiments of the invention, the lubricant is selected from the group consisting of zinc stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium stearyl fumarate, and any combination thereof.

In some embodiments of the invention, the lubricant is preferably magnesium stearate, which is present in an amount of about 0.1% to 2%, preferably about 0.3% to 1%, all by mass.

Furthermore, the Zanbutritinib oral solid tablet provided by the invention further comprises a coating agent.

In some embodiments of the invention, the coating agent is selected from the group consisting of opadry film coating powder, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, and any combination thereof. Preferably opadry film coating powder.

In one aspect of the present invention, the present invention provides a method for preparing the Zanubrutinib oral solid preparation, wherein the granulation process is selected from powder direct compression, dry granulation and wet granulation, and preferably wet granulation.

In one aspect of the present invention, the present invention provides a method for preparing the Zanubrutinib oral solid tablet, which comprises the following steps:

(1) mixing the Zanubrutinib drug substance with excipients (including, but not limited to, fillers, binders, disintegrants, wetting agents, glidants and lubricants);

(2) wet granulating the mixture of Zanubrutinib drug substance and excipient with purified water, or organic agents (including but not limited to ethanol, acetone), or aqueous or organic solutions containing binders, drying and granulating;

(3) optionally, mixing the whole granulate with additional excipients (including but not limited to fillers, lubricants, glidants) and compressing into a plain tablet;

(4) optionally, the plain tablets are coated,

wherein, if step (3) is not performed, the whole granules obtained in step (2) are compressed into a plain tablet.

In some embodiments of the invention, the organic reagent in step (2) is selected from the group consisting of ethanol, acetone, and combinations thereof.

In some embodiments of the invention, the additional excipient in step (3) is selected from the group consisting of fillers (e.g. microcrystalline cellulose), lubricants (e.g. magnesium stearate), glidants (e.g. colloidal silicon dioxide), and any combination thereof.

In the above preparation method, specific examples and contents of the filler, the binder, the disintegrant, the wetting agent, the glidant, the lubricant, and the coating are as described above.

In the above production method, "mixing" in the above production step (1) is performed by a commonly used mixing method. "mixing" is carried out using equipment such as a hopper mixer, vertical granulator, model FLO-5M, V mixer, tumbler mixer, etc.

In the above production method, the granulation in the above production step (2) may be performed using a usual granulation method. The granulation is carried out using equipment such as a wet granulator or the like. Compression is carried out using a conventional tablet press, such as ZP 10A. After tableting, if necessary, "drying" may be performed. For drying, any method used for drying the formulation may be generally used, for example, vacuum drying, fluidized bed drying, and the like. The following terms, as may be used herein, are used in accordance with the following definitions.

All ranges cited herein are inclusive, unless expressly stated to the contrary; that is, the range includes the values of the upper and lower limits of the range, as well as all values in between. For example, temperature ranges, percentages, equivalent ranges, and the like, as described herein, include the upper and lower limits of the ranges, and any value for the continuum between them.

The term "mass percentage" as used herein describes the content of drug substance Zanubrutinib and various excipients, calculated relative to the total mass of the oral solid tablet.

The term "formulation" as used herein refers to a mixture, aggregate, solution or other combination of substances including an Active Pharmaceutical Ingredient (API) that is suitable for a particular route of administration, e.g., a formulation suitable for compression into a tablet designed for oral administration in the treatment, management, prevention, etc. of a disease state or condition in a patient.

The "coating" used herein is not limited to the case of coating the entire surface of the coated object (plain tablet containing Zanubrutinib) but may also refer to the case of partially coating the coated object, absorbing or adsorbing an enteric coating component in the coated object, or coating the plain tablet of the core. The hardness of the oral solid tablet prepared according to the invention is 60N-220N, and the dissolution rate in 30 minutes is more than 85%.

In some embodiments of the invention, the amount of Zanubrutinib in the solid oral tablets is generally from about 70mg to about 400mg per tablet, preferably about 80mg, 160mg or 320mg per tablet.

In some embodiments of the present invention, one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents may also be included in the solid oral tablets to provide pharmaceutically elegant and palatable preparations.

In some embodiments of the invention, the solid oral tablet may be prepared using a variety of possible shapes (ellipsoid, capsule, biconvex circular lamp).

Drawings

Fig. 1 is an X-ray powder diffraction pattern of form a of Zanubrutinib.

FIG. 2 is a graph showing the cumulative dissolution rate (in vitro dissolution) of the drug in the Zanbutritinib oral solid tablet of example 1.

Fig. 3 is a graph showing the cumulative dissolution rate (in vitro dissolution) of the drug in Zanubrutinib oral solid tablets of examples 8 and 9. Among them, the drug dissolution rate of example 8 is significantly superior to that of example 9.

The specific implementation mode is as follows:

the following examples may assist those skilled in the art in a more complete understanding of the present invention, but are not intended to limit the invention in any way. Hereinafter, unless otherwise specified, the temperature is in ° c. Reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI and used without further purification unless otherwise specified.

Example 1

Preparation of Zanbrutinib oral solid tablet with specification of 160mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: lactose 53.2g, croscarmellose sodium 2g, sodium lauryl sulfate 1g and Zanubrutinib 34.8g were added to a high shear granulator (MYCROMIX, manufactured by BOSCH) and mixed for 5 minutes, an appropriate amount of purified water was added to granulate, and after drying and straightening, colloidal silicon dioxide 4.5g, microcrystalline cellulose 4g and magnesium stearate 0.5g were added and mixed. Mixing, and tabletting to obtain plain tablet. The above plain tablets were coated with 2.4g of opadry to obtain oral solid tablets containing Zanubrutinib.

Drug cumulative dissolution (in vitro dissolution) test: in vitro dissolution test was performed by using an automatic sampling dissolution apparatus (model: 708+850DS, available from AGILENT), USP <711> "dissolution rate" was selected by basket method, the temperature of the water bath of the automatic sampling dissolution apparatus was set at 37 + -0.5 deg.C, the rotation speed was 100rpm, and the volume was 900mL using a dissolution medium of pH 1.2(HCl) + 0.5% SLS. Sampling at 10min, 15min, 30min, 45min and 60min respectively, filtering all samples with 0.45 μm filter membrane, and determining and analyzing according to the dissolution rate determination method. As shown in figure 2, the oral solid tablet of Zanbutritinib of the invention can dissolve more than 90% of Zanbutritinib in a pH 1.2(HCl) + 0.5% SLS medium within 30min, and can meet the requirement of quick release.

The following examples 2 to 12 were each measured for the cumulative dissolution of the drug (in vitro dissolution) according to the method of example 1.

Example 2

Preparation of Zanbrutinib oral solid tablet with specification of 160mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 55.6g of lactose, 2.2g of croscarmellose sodium, 1.1g of sodium lauryl sulfate, 4.3g of colloidal silicon dioxide and 36.2g of Zanubrutinib were added to a high shear granulator and mixed for 5 minutes, an appropriate amount of purified water was added to granulate, and after drying, granules were sized, and 0.5g of magnesium stearate was added and mixed. Mixing and tabletting to obtain the plain tablet, namely the oral solid tablet containing Zanbutritinib.

Drug cumulative dissolution (in vitro dissolution) test: approximately 90% of Zanubrutinib was dissolved at 30 min.

Example 3

Preparation of Zanbrutinib oral solid tablet with specification of 160mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 49.2g of lactose, 2g of croscarmellose sodium, 1g of sodium lauryl sulfate and 33.3g of Zanubrutinib were added to a high shear granulator and mixed for 5 minutes, 2g of an aqueous hypromellose solution was added to granulate, after drying, the granules were sized, and 4g of colloidal silicon dioxide, 8g of microcrystalline cellulose and 0.5g of magnesium stearate were added and mixed. Mixing and tabletting to obtain the plain tablet, namely the oral solid tablet containing Zanbutritinib.

Example 4

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 50g of Zanbrutinib, 4g of croscarmellose sodium, 12.0g of colloidal silicon dioxide, 1g of sodium lauryl sulfate and 32.5g of microcrystalline cellulose were sieved and mixed in a high shear granulator, and then 0.5g of magnesium stearate was added and mixed uniformly. And directly tabletting the mixed powder to obtain the plain tablets. The above plain tablets were coated with a coating solution containing 2.4g of opadry to obtain oral solid tablets containing Zanubrutinib.

Drug cumulative dissolution (in vitro dissolution) test: the dissolution (%) of the drug at 30min was about 80%.

Example 5

Preparation of Zanbrutinib oral solid tablet with specification of 80mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: after 23.8g of lactose, 40g of microcrystalline cellulose, 2g of croscarmellose sodium, 1g of sodium lauryl sulfate, 4g of colloidal silicon dioxide and 26.7g of Zanubrutinib were added to the fluidized bed, an aqueous solution containing 2g of hypromellose was sprayed for granulation, and magnesium stearate was added after drying and mixing. Mixing, and tabletting to obtain plain tablet. The above plain tablets were coated with a coating solution containing 1.5g of opadry to obtain oral solid tablets containing Zanubrutinib.

Example 6

Preparation of Zanbrutinib oral solid tablet with specification of 80mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 26.7g of Zanbrutinib, 2g of croscarmellose sodium, 4g of colloidal silicon dioxide, 1g of sodium lauryl sulfate, 35.8g of lactose and 30g of silicified microcrystalline cellulose are sieved and mixed in a high shear granulator, 0.5g of magnesium stearate is added and mixed homogeneously. The powder is directly compressed into tablets and coated by an Opadry coating solution to obtain oral solid tablets containing Zanbutritinib.

Example 7

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 50.0g of Zanbrutinib, 4g of croscarmellose sodium, 8g of colloidal silicon dioxide, 1g of sodium lauryl sulfate and 36.5g of lactose were sieved and mixed in a high shear granulator, and then 0.5g of magnesium stearate was added and mixed well. Directly tabletting the powder to obtain a plain tablet, namely the oral solid tablet containing the Zanbutritinib.

Drug cumulative dissolution (in vitro dissolution) test: the drug content is about 40% in 30 min.

Example 8

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 50.0g of Zanbrutinib, 36.5g of microcrystalline cellulose, 4g of croscarmellose sodium, 8g of colloidal silicon dioxide, 1g of sodium lauryl sulfate were sieved and mixed in a high shear granulator, and 0.5g of magnesium stearate was added and mixed well. Directly tabletting the powder to obtain a plain tablet, namely the oral solid tablet containing the Zanbutritinib.

Drug cumulative dissolution (in vitro dissolution) test: the dissolution curve of the drug is shown in fig. 3, and it can be seen that the dissolution is more than 80% at 30 min.

Example 9

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: 60g of Zanbrutinib, 33.7g of microcrystalline cellulose, 4g of croscarmellose sodium, 0.8g of colloidal silicon dioxide, 1g of sodium lauryl sulfate were sieved and mixed in a high shear granulator, and 0.5g of magnesium stearate was added and mixed well. Directly tabletting the powder to obtain a plain tablet, namely the oral solid tablet containing the Zanbutritinib.

Drug cumulative dissolution (in vitro dissolution) test: the dissolution curve of the drug is shown in FIG. 3, and it can be seen that the dissolution is less than 60% at 30min

Example 10

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: lactose 53.2g, croscarmellose sodium 2g, sodium lauryl sulfate 1g and Zanubrutinib 34.8g were added to a high shear granulator (MYCROMIX, manufactured by BOSCH) and mixed for 5 minutes, an appropriate amount of purified water was added to granulate, and after drying and straightening, colloidal silicon dioxide 4.5g, microcrystalline cellulose 4g and magnesium stearate 0.5g were added and mixed. Mixing and tabletting to obtain the plain tablet, namely the oral solid tablet containing the Zanbutritinib.

Drug cumulative dissolution (in vitro dissolution) test: the dissolution (%) of the drug at 60min was about 80%.

Example 11

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

the preparation process comprises the following steps: according to a similar manner to example 10, an oral solid tablet containing Zanubrutinib may be prepared.

Drug cumulative dissolution (in vitro dissolution) test: the dissolution rate (%) of the medicine in 60min is less than 80%.

Example 12

Preparation of Zanbrutinib oral solid tablet with specification of 320mg

The prescription is (per 100g of the tablet):

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications within the scope of the following claims. The documents to which this disclosure relates are incorporated herein by reference.

Claims

1. An oral solid tablet comprising Zanubrutinib, comprising: (1) 20-70% of Zanbrutinib, preferably 30-50%, all of which are mass percent; (2) one or more pharmaceutically acceptable excipients.

2. The oral solid tablet of claim 1, wherein the Zanubrutinib is form a, amorphous, or a mixture of form a and amorphous.

3. The oral solid tablet of claim 1 or 2, wherein the excipient is selected from the group consisting of fillers, binders, disintegrants, wetting agents, glidants, lubricants, and any combination thereof.

4. The oral solid tablet of claim 3, wherein the filler is selected from the group consisting of starch, sucrose, microcrystalline cellulose, mannitol, lactose, pregelatinized starch, glucose, maltodextrin, cyclodextrin, cellulose, silicified microcrystalline cellulose, and any combination thereof.

5. The oral solid tablet of claim 4, wherein the filler is lactose, and the content of lactose is 20 to 70%, preferably 40 to 60%, all by mass.

6. The oral solid tablet of claim 4, wherein the filler is microcrystalline cellulose, and the content of the microcrystalline cellulose is 10% to 50%, preferably 30% to 50%, by mass.

7. The oral solid tablet of claim 4, wherein the filler is a combination of lactose and microcrystalline cellulose, the lactose and microcrystalline cellulose being present in an amount of 0-70% and 0-50%, preferably 40-60% and 4-10%, respectively, by mass.

8. The oral solid tablet of claim 3, wherein the binder is selected from the group consisting of starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, gelatin, sucrose, and any combination thereof.

9. The oral solid tablet of claim 8, wherein the binder is hypromellose, and the content of hypromellose is 0-10%, preferably 0-5%, by mass.

10. The oral solid tablet of claim 3, wherein the disintegrant is selected from the group consisting of sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, croscarmellose, methylcellulose, pregelatinized starch, sodium alginate, and any combination thereof.

11. The oral solid tablet of claim 10, wherein the disintegrant is croscarmellose sodium, and the content of the croscarmellose sodium is 0.5% to 5%, preferably 1% to 3%, all by mass.

12. The oral solid tablet of claim 3, wherein the wetting agent is sodium lauryl sulfate, and the content of the sodium lauryl sulfate is 0 to 5 percent, preferably 0.5 to 1.0 percent, all by mass.

13. The oral solid tablet of claim 3, wherein the glidant is selected from powdered cellulose, magnesium trisilicate, colloidal silicon dioxide, talc, and any combination thereof.

14. Oral solid tablet according to claim 13, wherein the glidant is colloidal silicon dioxide, the content of colloidal silicon dioxide being 0.1-20%, preferably 4-8%, all in mass percent.

15. The oral solid tablet of claim 3, wherein the lubricant is selected from zinc stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium fumarate stearate, and any combination thereof.

16. The oral solid tablet of claim 15, wherein the lubricant is magnesium stearate, and the content of magnesium stearate is 0.1% to 2%, preferably 0.3% to 1%, all by mass.

17. The oral solid tablet of any one of claims 1 to 16, further comprising a coating agent selected from the group consisting of opadry film coating powder, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, and any combination thereof, preferably opadry film coating powder.

18. A process for the preparation of an oral solid tablet according to any one of claims 1 to 17, wherein the granulation process of the oral solid tablet is selected from powder direct compression, dry granulation, wet granulation, preferably wet granulation.

19. A method of making the oral solid tablet of any one of claims 1-17, comprising the steps of:

(1) mixing the Zanubrutinib with one or more excipients;

(2) wet granulating the mixture of Zanubrutinib and one or more excipients with purified water, or organic agent, or aqueous or organic solution containing binder, drying and straightening;

(3) optionally, mixing the whole granules with an additional excipient and compressing into a plain tablet;

(4) optionally, the plain tablets are coated,

wherein, if step (3) is not performed, the whole granulated particles obtained in step (2) are compressed into a plain tablet.

20. The method of claim 19, wherein the organic reagent in step (2) is selected from the group consisting of ethanol, acetone, and combinations thereof.

21. The process according to claim 19 or 20, wherein the additional excipient in step (3) is selected from the group consisting of fillers, lubricants, glidants and any combination thereof.